Veeva Systems (VEEV) Raymond James 2024 TMT & Consumer Conference summary

Key takeaways from leadership

• Strong execution across both short- and long-term initiatives, with several products and projects now reaching fruition after years of development.

• The company sees significant untapped opportunity in life sciences, with new product areas and markets still in early stages.

• A disciplined, centralized hiring process and a well-defined operating model foster a strong, cohesive culture that is difficult to replicate.

Product innovation and roadmap

• Recent CRM releases include advanced features like AI-powered CRM Bot, Voice Control, and Campaign Manager, integrating sales, marketing, and medical in a single database.

• Vault CRM migration is progressing, with four top 20 customers committed and most migration decisions expected by end of 2026.

• Integration of sales, service, and marketing on a unified platform is a first in the industry, unlocking new innovation potential.

Growth strategy and financial targets

• Commercial segment targets $2 billion revenue by 2030, driven by Crossix, Link, and Compass data products, with CRM migrations laying groundwork for future growth.

• R&D segment targets $4 billion by 2030, with growth broad-based across clinical, quality, regulatory, and safety suites.

• Subscription revenue is expected to grow at 14% annually, with services in high single digits; growth projections are built bottom-up by product area.